BioAsset

Insights / All articles

Research

Parasites as Biotech Assets: From Disease to Drug Discovery

By Brendan Seo, Research Analyst at BioAsset · 5 slides

Parasites have mostly been studied as something to eliminate. They are now also being treated as a source of molecules for drug discovery, and that raises a question about who benefits from them.

Parasitic diseases affect over 200 million people worldwide, with the highest prevalence in sub-Saharan Africa, South Asia and parts of Latin America. Malaria alone caused over 249 million cases and 600,000 deaths in 2022, according to WHO figures. A prevalence map of intestinal parasites (Seay, 2018) puts much of sub-Saharan Africa, along with parts of South and Southeast Asia and Latin America, in its very high band of more than 25%.

Most research has focused on eliminating parasites because of their role in causing disease. However, parasites also interact closely with human biological systems and produce molecules that influence how cells and immune responses function.

What researchers have found

Parasites produce specialized proteins and metabolites that allow them to survive inside the human body and avoid immune detection. One illustration from Nature Reviews Immunology shows a helminth releasing cytokine mimics, non-protein signatures and cystatins that act on immune cells such as macrophages and dendritic cells.

These molecules can regulate immune responses. That is important, since over 50 million people are affected by autoimmune diseases globally. Researchers are now studying parasite-derived compounds for use in autoimmune conditions, and for emerging applications in cancer research.

From threat to input

Advances in genomics and biobanking have made it possible to collect and store biological samples at scale. Today, more than 500 million samples are stored in biobanks worldwide. These samples are used in drug discovery pipelines, where compounds are tested for medical applications.

Developing a new drug can take 10 to 15 years, which makes access to diverse biological data critical. The process runs through nine stages: discovery, preclinical studies, a first regulatory filing, three phases of clinical trials, a regulatory filing for approval, access to the drug and post-approval studies.

This shift has changed how parasites are viewed. Instead of only being studied as threats, they are now seen as valuable inputs in the early stages of drug development, with the potential to contribute to multiple therapeutic areas.

Who benefits

Parasitic diseases are most common in regions such as sub-Saharan Africa, yet much of the value generated from these biological resources is concentrated in developed countries. The global pharmaceutical industry generates over $1.5 trillion annually, while the regions supplying key materials often receive limited direct benefits.

As biotechnology advances, compounds from parasites are becoming more important in early-stage research, especially in areas that involve immune regulation and disease treatment. Biological materials are playing a growing role as valuable inputs in drug discovery.

The challenge moving forward is how these resources are managed. Questions around ownership, access and benefit sharing will play a key role in shaping future outcomes.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.